Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UGT8 | Q16880 | 18/20 | 0.68 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21813973 | 0.91 | UGT8 (0.69) | UGT8CYP11B2KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL30845007 | 0.91 | UGT8 (0.69) | UGT8CYP11B2KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL21814139 | 0.81 | UGT8 (1.00) | UGT8 | |
| SCHEMBL30844976 | 0.81 | UGT8 (1.00) | UGT8 | |
| SCHEMBL21813409 | 0.81 | UGT8 (0.47) | UGT8CYP11B2KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL21813961 | 0.80 | UGT8 (0.56) | UGT8CYP11B2KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL21814038 | 0.80 | UGT8 (0.76) | UGT8KDM4EALDH1A1SMN1; SMN2TDP1 | |
| SCHEMBL21813999 | 0.79 | UGT8 (0.95) | UGT8 | |
| SCHEMBL21813358 | 0.79 | UGT8 (0.89) | UGT8 | |
| SCHEMBL21814002 | 0.77 | UGT8 (0.77) | UGT8KDM4EALDH1A1SMN1; SMN2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113423711-B | Thieno [3,2-B ] pyridine derivatives as UDP glycosyltransferase inhibitors and methods of use thereof | 建新公司 | 2024-03-15 | — | — | CN | claimed |
| CN-113423711-B | Thieno [3,2-B ] pyridine derivatives as UDP glycosyltransferase inhibitors and methods of use thereof | 建新公司 | 2024-03-15 | — | — | CN | disclosed |
| EP-3861000-A1 | THIENO[3,2-B]PYRIDINE DERIVATIVES AS UDP GLYCOSYLTRANSFERASE INHIBITORS AND METHODS OF USE | Genzyme Corporation (US) | 2021-08-11 | — | — | EP | disclosed |
| WO-2020072504-A1 | THIENO[3,2-B]PYRIDINE DERIVATIVES AS UDP GLYCOSYLTRANSFERASE INHIBITORS AND METHODS OF USE | GENZYME CORPORATION (US) | 2020-04-09 | — | — | WO | disclosed |
| US-20200102324-A1 | UDP GLYCOSYLTRANSFERASE INHIBITORS AND METHODS OF USE | GENZYME CORPORATION | 2020-04-02 | — | — | US | disclosed |
| US-20200102324-A1 | UDP GLYCOSYLTRANSFERASE INHIBITORS AND METHODS OF USE | GENZYME CORPORATION | 2020-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200102324-A1 | UDP GLYCOSYLTRANSFERASE INHIBITORS AND METHODS OF USE | MAN2B1, GAA, GBA1 | UGT8 74/4885CYP11B2 3451/4885KDM4E 647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.